IGM BiosciencesIGMS
About: IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Employees: 149
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
68% more call options, than puts
Call options by funds: $377K | Put options by funds: $224K
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
15% more funds holding
Funds holding: 72 [Q3] → 83 (+11) [Q4]
0.09% more ownership
Funds ownership: 63.52% [Q3] → 63.61% (+0.09%) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
63% less capital invested
Capital invested by funds: $357M [Q3] → $133M (-$224M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for IGMS.
Financial journalist opinion
